Precigen Inc (PGEN)
1.42
+0.02
(+1.43%)
USD |
NASDAQ |
May 03, 16:00
1.425
0.00 (0.00%)
After-Hours: 20:00
Precigen SG&A Expense (Quarterly): 10.26M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 10.26M |
September 30, 2023 | 9.196M |
June 30, 2023 | 9.316M |
March 31, 2023 | 11.64M |
December 31, 2022 | 11.51M |
September 30, 2022 | 10.14M |
June 30, 2022 | 12.67M |
March 31, 2022 | 13.69M |
December 31, 2021 | 11.80M |
September 30, 2021 | 10.98M |
June 30, 2021 | 14.95M |
March 31, 2021 | 18.70M |
December 31, 2020 | 30.04M |
September 30, 2020 | 22.31M |
June 30, 2020 | 17.87M |
March 31, 2020 | 21.49M |
December 31, 2019 | 0.208M |
September 30, 2019 | 22.19M |
June 30, 2019 | 19.25M |
March 31, 2019 | 31.05M |
December 31, 2018 | 12.29M |
September 30, 2018 | 38.71M |
June 30, 2018 | 34.43M |
March 31, 2018 | 39.74M |
Date | Value |
---|---|
December 31, 2017 | 17.42M |
September 30, 2017 | 39.28M |
June 30, 2017 | 38.84M |
March 31, 2017 | 35.14M |
December 31, 2016 | 35.36M |
September 30, 2016 | 33.81M |
June 30, 2016 | 30.26M |
March 31, 2016 | 42.88M |
December 31, 2015 | 34.74M |
September 30, 2015 | 23.02M |
June 30, 2015 | 23.67M |
March 31, 2015 | 27.63M |
December 31, 2014 | 19.78M |
September 30, 2014 | 14.85M |
June 30, 2014 | 15.38M |
March 31, 2014 | 13.64M |
December 31, 2013 | 12.30M |
September 30, 2013 | 7.407M |
June 30, 2013 | 7.434M |
March 31, 2013 | 6.48M |
December 31, 2012 | 5.758M |
September 30, 2012 | 5.046M |
June 30, 2012 | 6.333M |
March 31, 2012 | 7.76M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.208M
Minimum
Dec 2019
30.04M
Maximum
Dec 2020
14.64M
Average
12.67M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
Cyclacel Pharmaceuticals Inc | 1.873M |
HealthEquity Inc | 45.85M |
Corvus Pharmaceuticals Inc | 1.652M |
Oragenics Inc | 1.754M |
MAIA Biotechnology Inc | 2.660M |